Home
/ OLYMVAX
/ Competitors

OLYMVAX Competitors and Similar CompaniesClear all

OLYMVAX's competitors and similar companies include UCB, Genentech and EMS Pharma.

	OLYMVAX Chengdu Olymvax Biopharmaceuticals (成都欧林生物科技股份有限公司) is a biopharmaceutical company that produces and sells vaccines.	UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions.	Genentech Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines.	EMS Pharma EMS Pharma is a company that specializes in the research, development, and manufacturing of pharmaceuticals.
Founding Date	Founding Date 2009	Founding Date 1928	Founding Date 1976	Founding Date 1964
Type	Type Public	Type Public	Type Subsidiary	Type Private
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development pharma
Locations	Locations Chengdu, CN HQ Chengdu, CN Chongqing, CN	Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more	Locations South San Francisco, US HQ Hillsboro, US Oceanside, US Portland, US South San Francisco, US South San Francisco, US South San Francisco, US see more	Locations BR HQ
Employees	Employees 470	Employees 9,052	Employees 18,077	Employees 12,7441% increase
Valuation ($)	Valuation ($) 592 m	Valuation ($) 34.3 b	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) ¥694.1m (FY, 2025)	Revenue (est.) €7.4b (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods ¥49.6m (FY, 2025)	Cost of goods €1.4b (FY, 2025)	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit ¥648.5m (FY, 2025)	Gross profit €7.2b (FY, 2025)	Gross profit N/A	Gross profit N/A
Net income	Net income ¥21.9m (FY, 2025)	Net income €1.6b (FY, 2025)	Net income N/A	Net income N/A